Stock Yards Bank & Trust Co. trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 1.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,813 shares of the company’s stock after selling 622 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Eli Lilly And Co were worth $8,671,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Sterling Investment Management Inc. increased its stake in Eli Lilly And Co by 3.7% during the second quarter. Sterling Investment Management Inc. now owns 8,026 shares of the company’s stock valued at $1,318,000 after acquiring an additional 287 shares during the period. Brasada Capital Management LP acquired a new position in shares of Eli Lilly And Co in the 2nd quarter worth approximately $1,261,000. Boenning & Scattergood Inc. boosted its holdings in shares of Eli Lilly And Co by 58.0% in the 2nd quarter. Boenning & Scattergood Inc. now owns 8,461 shares of the company’s stock worth $1,389,000 after acquiring an additional 3,105 shares in the last quarter. PBMares Wealth Management LLC acquired a new position in shares of Eli Lilly And Co in the 2nd quarter worth approximately $210,000. Finally, RDA Financial Network acquired a new position in shares of Eli Lilly And Co in the 2nd quarter worth approximately $207,000. Hedge funds and other institutional investors own 77.32% of the company’s stock.

NYSE:LLY traded up $1.73 during trading hours on Tuesday, hitting $163.88. 2,641,585 shares of the stock were exchanged, compared to its average volume of 4,230,432. The company’s 50 day moving average is $156.52 and its two-hundred day moving average is $145.88. The company has a market capitalization of $155.09 billion, a P/E ratio of 27.00, a price-to-earnings-growth ratio of 1.51 and a beta of 0.26. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $170.75. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.48 by $0.27. The company had revenue of $5.86 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.33 EPS. On average, equities research analysts expect that Eli Lilly And Co will post 6.82 EPS for the current year.

In related news, major shareholder Lilly Endowment Inc sold 230,000 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $160.12, for a total value of $36,827,600.00. Following the completion of the sale, the insider now owns 112,593,158 shares in the company, valued at approximately $18,028,416,458.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Alfonso G. Zulueta sold 17,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $162.94, for a total transaction of $2,769,980.00. Following the completion of the sale, the senior vice president now owns 39,646 shares of the company’s stock, valued at approximately $6,459,919.24. The disclosure for this sale can be found here. Insiders have sold a total of 797,899 shares of company stock valued at $130,292,658 in the last quarter. Corporate insiders own 0.09% of the company’s stock.

Several research analysts have recently commented on the company. Mizuho boosted their target price on Eli Lilly And Co from $155.00 to $164.00 and gave the stock a “neutral” rating in a report on Monday, June 29th. Guggenheim raised Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 target price on the stock in a report on Tuesday, June 16th. Cfra boosted their target price on Eli Lilly And Co from $146.00 to $167.00 and gave the stock a “hold” rating in a report on Friday, April 24th. JPMorgan Chase & Co. boosted their target price on Eli Lilly And Co from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Wednesday, June 17th. Finally, UBS Group downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $157.00 to $158.00 in a report on Monday, April 20th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $168.58.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Preferred Stock

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.